(Information sent by the signatory company)
- Dragonfly has received a milestone payment following dosing of the first patient in AbbVie's Phase 1 clinical trial evaluating DF4101/ABBV-303
This is the eighth drug to use the Dragonfly platform technology and the sixth TriNKET® to enter clinical trials.
WALTHAM, Mass., March 5, 2024 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical-stage biotechnology company developing novel immunotherapies, today announced receipt of a significant payment following dosing of the first patient in a trial clinical trial conducted by AbbVie (NYSE: ABBV) to evaluate ABBV-303, a TriNKET® targeted solid tumor.
ABBV-303, an investigational drug being developed for the treatment of solid tumors, is the eighth drug using the Dragonfly platform technology to enter the clinic, and the first TriNKET® drug candidate licensed from AbbVie to enter the clinic. the clinic. The Phase 1 clinical trial, conducted by AbbVie, evaluates ABBV-303 alone and in combination with AbbVie's budigalimab (ABBV-181), in solid tumors.
"We are delighted that AbbVie has brought ABBV-303 into the clinic," said Bill Haney, CEO and co-founder of Dragonfly. "AbbVie is a global leader in advancing novel treatments for some of the most complex diseases and an excellent partner. We look forward to continued success and rapid progress with the AbbVie team to advance potential new treatment options for patients."
Additional information about the Phase 1 M24-122 trial can be found at: https://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT06158958).
About DragonflyDragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel therapies that harness the body's immune system to deliver innovative treatments to patients. In addition to a suite of advanced programs in the clinic, Dragonfly has a broad pipeline of wholly-owned preclinical candidates discovered using its proprietary platforms that are progressing toward the clinic, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a wide range of disease areas.
For more information, visit: www.dragonflytx.com https://www.linkedin.com/company/dragonfly-therapeutics-inc./ https://twitter.com/dragonflytx
DRAGONFLY MEDIA CONTACT:Anne E. Deconinck | anne@dragonflytx.com
Logo - https://mma.prnewswire.com/media/390962/...
View original content: https://www.prnewswire.com/news-releases/dragonfly-recibe-un-pago-por-hito-tras-la-dosificacion-del-primer-paciente-en-el-ensayo-clinico-de-abbvie-302079563.html
